The MHRA has issued two drug safety alerts directed at nicorandil (Ikorel) and its potential effect on ulcer development, and the need to prescribe levonorgestrel-releasing intrauterine systems (IUS) by brand name.

The MHRA is warning that nicorandil’s second line treatment for stable angina can potentially lead to ulcers progressing to complications unless the drug is stopped.

Additionally, for American products consisting of levonorgestrel 52mg, the MHRA has stated that two brands are now available which have some important differences, so products should be prescribed by brand name.